These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29386004)

  • 1. Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT.
    Guo SS; Hu W; Chen QY; Li JM; Zhu SH; He Y; Li JW; Xia L; Ji L; Lin CY; Liu LT; Tang LQ; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Hong MH; Shao JY; Sun Y; Ma J; Fan YY; Mai HQ
    BMC Cancer; 2018 Jan; 18(1):114. PubMed ID: 29386004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy.
    Huang TL; Chien CY; Tsai WL; Liao KC; Chou SY; Lin HC; Dean Luo S; Lee TF; Lee CH; Fang FM
    Head Neck; 2016 Apr; 38 Suppl 1():E1026-32. PubMed ID: 26041548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires.
    Bian X; Song T; Wu S
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):109-19. PubMed ID: 25231774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
    Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
    Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between the Comprehensive Nutritional Index and the EORTC QLQ-H&N35 in Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy.
    He Y; Chen L; Chen L; Hu W; Wang C; Tang L; Mai H; Li J; Wu L; Fan Y
    Nutr Cancer; 2017 Apr; 69(3):436-443. PubMed ID: 28287323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma.
    Pan XB; Huang ST; Chen KH; Jiang YM; Ma JL; Qu S; Li L; Chen L; Zhu XD
    Oncotarget; 2017 Jul; 8(28):46211-46218. PubMed ID: 28515352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
    Tang LQ; Hu DP; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Wen SH; Peng YT; Chen WH; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mai HQ
    PLoS One; 2015; 10(4):e0122965. PubMed ID: 25874450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy.
    Huang TL; Tsai MH; Chuang HC; Chien CY; Lin YT; Tsai WL; Fang FM
    Radiat Oncol; 2020 Apr; 15(1):84. PubMed ID: 32307024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study.
    Fang FM; Chien CY; Tsai WL; Chen HC; Hsu HC; Lui CC; Huang TL; Huang HY
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):356-64. PubMed ID: 18355980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma.
    Tsai WL; Chien CY; Huang HY; Liao KC; Fang FM
    Qual Life Res; 2013 May; 22(4):715-23. PubMed ID: 22669472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of masticatory muscle involvement in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Kang M; Zhou P; Liao X; Xu M; Wang R
    Oral Oncol; 2017 Dec; 75():100-105. PubMed ID: 29224805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
    Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of pretreatment tumor apparent diffusion coefficient values in nasopharyngeal carcinoma.
    Yan DF; Zhang WB; Ke SB; Zhao F; Yan SX; Wang QD; Teng LS
    BMC Cancer; 2017 Oct; 17(1):678. PubMed ID: 29020937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
    Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
    Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
    Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
    Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
    Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasopharyngeal carcinoma: Experience and treatment outcome with radical conformal radiotherapy from a tertiary care center in India.
    Kunheri B; Agarwal G; Sunil PS; Nair AR; Pushpaja KU
    Indian J Cancer; 2017; 54(3):502-507. PubMed ID: 29798947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.